@moelsoud.bsky.social
The FDA has approved the weight-loss drug Zepbound for treating obstructive sleep apnea (OSA) in patients with obesity. Developed by Eli Lilly, the drug is part of the GLP-1 receptor agonists class and requires a low-calorie diet and increased physical activity as part of the treatment plan.
December 21, 2024 at 8:32 PM
The FDA has approved the weight-loss drug Zepbound for treating obstructive sleep apnea (OSA) in patients with obesity. Developed by Eli Lilly, the drug is part of the GLP-1 receptor agonists class and requires a low-calorie diet and increased physical activity as part of the treatment plan.